Year: 2021
Type: review
Abstract: Creatine is a key player in heart contraction and energy metabolism. Creatine supplementation (throughout the paper, only supplementation with creatine monohydrate will be reviewed, as this is by far the most used and best-known way of supplementing creatine) increases creatine content even in the normal heart, and it is generally safe. In heart failure, creatine and phosphocreatine decrease because of decreased expression of the creatine transporter, and because phosphocreatine degrades to prevent adenosine triphosphate (ATP) exhaustion. This causes decreased contractility reserve of the myocardium and correlates with left ventricular ejection fraction, and it is a predictor of mortality. Thus, there is a strong rationale to supplement with creatine the failing heart. Pending additional trials, creatine supplementation in heart failure may be useful given data showing its effectiveness (1) against specific parameters of heart failure, and (2) against the decrease in muscle strength and endurance of heart failure patients. In heart ischemia, the majority of trials used phosphocreatine, whose mechanism of action is mostly unrelated to changes in the ergogenic creatine-phosphocreatine system. Nevertheless, preliminary data with creatine supplementation are encouraging, and warrant additional studies. Prevention of cardiac toxicity of the chemotherapy compounds anthracyclines is a novel field where creatine supplementation may also be useful. Creatine effectiveness in this case may be because anthracyclines reduce expression of the creatine transporter, and because of the pleiotropic antioxidant properties of creatine. Moreover, creatine may also reduce concomitant muscle damage by anthracyclines.
Source: Nutrients
DOI: 10.3390/nu13041215
Author: Maurizio Balestrino
Institutions: Ospedale Policlinico San Martino, University of Genoa
Language: English
Subfield: Nutrition and Dietetics
Field: Nursing
Domain: Health Sciences
Keywords: creatine supplementation, creatine monohydrate, heart failure, myocardial energy metabolism, phosphocreatine, creatine transporter, cardiac contractility, left ventricular ejection fraction, mortality prediction, heart ischemia, anthracycline cardiotoxicity, antioxidant activity, muscle damage
Open Access status: gold
Estimated APC paid: $2,592
Funders: Alzchem Group, Ministero della Salute
OpenAlex ID: W3147484503
